Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 187 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Living Donor Clear all

Conditions: Kidney Transplantation
Interventions: Mycophenolic Acid, Standard of Care: CNI and MPA; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Kidney Transplantation
Interventions: Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI; Drug · Biological
Lead sponsor: Singulera Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota

Conditions: Renal Transplant Rejection
Interventions: Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy; Drug · Other · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Kidney Transplantation, End Stage Renal Disease
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 8,951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
Interventions: TTAX01, Standard Care; Biological · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 16
States / cities: San Francisco, California • Sylmar, California • Miami, Florida + 13 more

Conditions: Transplanted Organ Rejection
Interventions: FCR001; Biological
Lead sponsor: Talaris Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 18
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 14 more

Conditions: Kidney Disease
Interventions: donor bone marrow infusion; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Miami, Florida

Conditions: End Stage Renal Disease
Interventions: rituximab; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Leukemia, Myeloma, Myeloproliferative Diseases
Interventions: Fludarabine, Melphalan, Alemtuzumab, Stem Cell infusion, Tacrolimus, Mini Methotrexate, G-CSF, Donor Lymphocyte Infusion (DLI), AP1903, Methylprednisolone, Questionnaire; Drug · Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Kidney Disease, End-Stage Renal Disease
Interventions: Additional education; Behavioral
Lead sponsor: St. Barnabas Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Livingston, New Jersey

Conditions: Mayer Rokitansky Kuster Hauser Syndrome, Absence of Uterus, Infertility of Uterine Origin
Interventions: Uterine Transplant; Other
Lead sponsor: John Goss; Other
Eligibility: 20 Years to 65 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fibrolamellar Hepatocellular Carcinoma, Hepatocellular Carcinoma (Fibrolamellar Variant), Hepatocellular Carcinoma
Interventions: living related donor partial liver transplantation, Total body irradiation, Bone marrow transplant from same donor, Cyclophosphamide, Mesna, Filgrastim, Tacrolimus, mycophenolate mofetil, Prednisone, Antithymocyte globulin, fludarabine; Procedure · Radiation · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 16 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Transplantation, Liver
Interventions: Serial blood sampling as described in protocol, Estimation of Creatinine Clearance at regular intervals; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Rochester, New York

Conditions: End Stage Renal Disease
Interventions: Expanded Tregs; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Immune System Disorder
Interventions: Isatuximab SAR650984, Acetaminophen (paracetamol) or equivalent, Ranitidine or equivalent, Diphenhydramine or equivalent, Methylprednisolone or equivalent, Montelukast or equivalent; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: San Francisco, California • Rochester, Minnesota • New York, New York + 1 more

Conditions: Burns Degree Third, Burn (Disorder), Burn Degree Second, Thermal Burn, Wound Heal
Interventions: Skin Xenotransplant, Autograft(ing); Drug · Procedure
Lead sponsor: XenoTherapeutics, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Phoenix, Arizona • Augusta, Georgia • Portland, Maine + 1 more

Conditions: Renal Transplant Rejection, Tolerance, Kidney Transplant
Interventions: Donor CD34+ and CD3+ cells; Biological
Lead sponsor: Jeffrey Veale, MD; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Kidney Diseases
Interventions: CT angiogram of the remaining kidney., Kidney Function study using Iothalamate & PAH as clearance markers; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Kidney Disease, End Stage Renal Disease
Interventions: Transplant education with video, Transplant education with speakers; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Not listed
Enrollment: 370 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Overland Park, Kansas • Springfield, Missouri • St Louis, Missouri + 1 more

Conditions: Human Immunodeficiency Virus, End Stage Renal Disease
Interventions: Kidney transplant; Procedure
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Metairie, Louisiana

Conditions: Liver Transplant
Interventions: MiMedx AmnioFix; Biological
Lead sponsor: Jaekeun Kim; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Living Donors, Nephrectomy, Kidney
Interventions: mHealth application; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Kidney Transplantation, Immunity, Immunosuppression
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Living Donor Kidney Transplantation
Interventions: Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 2
States / cities: Palo Alto, California • Chicago, Illinois

Search by objective public record fields.

Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

Live Kidney Donor Study

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

Living-Related Donor Bone Marrow Immunoregulation in Kidney Transplants

Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

Increasing Kidney Transplant Among Blacks on the Transplant Waiting List

Uterine Transplant for Women With Absolute Uterine Factor Infertility (AUFI)

Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)

PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients

Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients

Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

Comparative Renal Function of Young (18-45 Years) and Ageing (55 Years and Above) Kidney Donors

Educating Missouri Patients About Preemptive Living Donor Transplantation

Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors

Biliary Anastomosis in Living Donor Liver Transplant With Amniotic Tissue

Pilot Study of an mHealth Intervention for Living Donor Follow-up

Protective Immunity Project 01

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation